Drugs / GSK3389245A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02491463 | Jul 2015 → Apr 2016 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3389245A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02491463 ↗ |
| Modality | Vaccine | “evaluated an investigational vaccine against RSV” PMID 31340042 ↗ May 2020 |
| Route | Intramuscular | “2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm” NCT02491463 ↗ |